Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.
about
Recent Treatments of Interstitial Lung Disease with Systemic SclerosisUpdate on biomarkers in systemic sclerosis: tools for diagnosis and treatmentA roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung diseaseTargeted Therapy in Systemic SclerosisAngiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patientsEmerging targets for the treatment of scleroderma.Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis.Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.Application of biomarkers to clinical trials in systemic sclerosis.Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosisCCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts.Sequential expression of IGF-IB followed by active TGF-β1 induces synergistic pulmonary fibroproliferation in vivo.Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations.Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis.Interleukin-4 in rheumatoid arthritis patients with interstitial lung disease: a pilot studyCirculating biomarkers of interstitial lung disease in systemic sclerosis.Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature.Molecular biomarkers in interstitial lung diseases.Facts and promises on lung biomarkers in interstitial lung diseases.Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course.Biomarkers in systemic sclerosis: Their potential to predict clinical courses.Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study.An update on biomarker discovery and use in systemic sclerosis.Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis.Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis.Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study.Cell surface expression of activating receptors and co-receptors on peripheral blood NK cells in systemic autoimmune diseases.Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients.
P2860
Q26773161-15CC5264-FEAF-4ADF-A186-1BFF174EC5A9Q26995542-DDFF86ED-AAF7-4A69-8E28-1E95B5871025Q27014138-8AB15D7D-D7BD-4608-B9A8-F8B11992D8D9Q28072943-9137BAB6-0CB1-4BC9-9B96-18F60E80861DQ33765684-16CE237C-D9DF-49E9-90D8-916EC0C4FB34Q34270856-D67948CC-9ABD-4D47-BB20-D77EED6C192FQ35064030-87C7E596-7195-487C-9696-5E9F222D7A85Q35566387-0E5D1081-07BD-46F3-91CC-E8F3630B9C47Q35681874-58A7A61E-DA2C-426B-A800-5E30BC247A10Q36364258-BD74E308-922D-4E0D-90B4-9CD75FBAB4C9Q36391220-CA99F50B-8B01-4939-90C0-2F04E53F0E89Q36454392-46C371E4-43E2-4AFD-98AF-83ECE187D3ABQ37443706-5D5727AB-EACA-4872-907E-17C107E200D4Q37689681-97F419CB-DC20-4C6A-8FF0-A9F73FA912C6Q37690843-16ED2E5C-A433-481D-83DF-002960923526Q38044387-9286786A-D38D-4B2F-B3B1-0D61016A36F5Q38090724-A639E7CC-FF6C-4935-BF27-8A0748A8808AQ38220769-96379F4B-607B-4501-BFDD-8A443A3BDCEDQ38543042-CDD296AB-1D80-497E-AB96-9B0694C9AB02Q38630663-5560CD97-4062-4724-8F92-A58CA127621BQ38701985-FA03E3C0-EBBA-4DC6-94CC-6D25AED2AA6EQ39061366-0F00CCCB-A233-4663-A5D9-EAA189BFD008Q39450087-8ACFE773-609E-4096-A020-85C6BB66DDCBQ40154356-3D7FC5FF-EAE4-49C7-93B8-B15434D62273Q42407453-E4813154-A84C-45AE-BDE4-19902569AC5CQ43836990-0560E368-4112-4C2A-B722-B748A384F658Q44131640-8829BE1A-8F6C-4161-8046-CC5C0DB09678Q46093248-DD01F89A-3FB4-4C4E-816B-7814992CB086Q47614995-598C661A-7674-44FD-B1DC-2BCE9D1B479C
P2860
Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bronchoalveoloar lavage fluid ...... n systemic sclerosis patients.
@en
Bronchoalveoloar lavage fluid ...... n systemic sclerosis patients.
@nl
type
label
Bronchoalveoloar lavage fluid ...... n systemic sclerosis patients.
@en
Bronchoalveoloar lavage fluid ...... n systemic sclerosis patients.
@nl
prefLabel
Bronchoalveoloar lavage fluid ...... n systemic sclerosis patients.
@en
Bronchoalveoloar lavage fluid ...... n systemic sclerosis patients.
@nl
P2093
P2860
P356
P1476
Bronchoalveoloar lavage fluid ...... n systemic sclerosis patients.
@en
P2093
Christian Meisel
Christian Witt
Doerte Huscher
Katrin Schmidt
Leif G Hanitsch
Lorena Martinez-Gamboa
Mike O Becker
Susan Meier
P2860
P2888
P356
10.1186/AR2766
P577
2009-07-17T00:00:00Z